DOI:
10.1055/s-00000077
Seminars in Thrombosis and Hemostasis
LinksClose Window
References
ROCKET AF Study Investigators.
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study.
Am Heart J 2010;
159 (3) 340-347, e1
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.